Skip to main content

Table 1 Select Baseline Demographic and Clinical Characteristics of the ETN + MTX Group*.

From: Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis

 

ETN + MTX

(n = 281)

Age, years

48.4 ± 12.0

Women, n (%)

248 (88.3)

Race, n (%)

 White

134 (47.7)

 Mestizo

60 (21.4)

 African-Latin American

39 (13.9)

 Other

48 (17.1)

BMI, kg/m2

26.4 ± 5.1

CRP, mg/L

20.7 ± 25.4

ESR, mm/h

43.2 ± 16.6

Disease duration, years

7.9 ± 7.0

RF positive, n (%)

242 (86.1)

DAS28-ESR

6.6 ± 0.7

HAQ total score

1.6 ± 0.7

PGA

6.7 ± 1.6

VAS Pain, mm (0–100 scale)

65.6 ± 21.3

  1. *Data are mean ± SD unless stated otherwise
  2. BMI body mass index, CRP C-reactive protein, DAS28-ESR 28-joint Disease Activity Score with erythrocyte sedimentation rate, ETN etanercept, HAQ Health Assessment Questionnaire, MTX methotrexate, PGA Physician Global Assessment, RF rheumatoid factor, SD standard deviation, VAS visual analog scale